Key Takeaways for CVS Health Stock as of August 2026
- Beat and Fade: CVS posted Q2 adjusted EPS of $2.58 against a $1.85 estimate on $106.1B revenue, up 7.3% YoY, and lifted 2026 adjusted EPS guidance to $7.90-$8.10, yet the stock fell ~6% on Aug 5.
- Street Conviction: 18 buys, 6 outperforms, and 3 holds anchor a $116 mean target that sits ~25% above the $93 close, with holds down from 7 a year ago.
- Model Upside: TIKR’s model pegs CVS at $132 by 2030, a 42% total return.
- 2027 Overhang: A first 2027 adjusted EPS view of at least $8.44 and a flagged Caremark membership decline sparked the post-earnings slide despite the raise.
CVS Health Stock Slid After a Record Quarter Ran Into a Cautious 2027 Setup
CVS Health stock (CVS) fell nearly 6% on August 5, even as the company posted its seventh consecutive earnings beat: adjusted EPS of $2.58 against a $1.85 consensus, on revenue of $106.1 billion that grew 7.3% year over year. The quarter was not close. It topped estimates by 73 cents.
Management raised the full-year bar to match. CVS lifted 2026 adjusted EPS guidance to $7.90-$8.10 from $7.30-$7.50, pushed its cash-flow-from-operations outlook to at least $11.5 billion from at least $9.5 billion, and pointed revenue toward at least $414 billion. The Aetna insurance unit, the segment that missed for much of 2024, drove the beat: its medical benefit ratio, the share of premiums spent on care, came in at 87.4%, down from 89.9% a year earlier and well inside the 90% analysts modeled.
So why did the stock drop? The problem sat in the outlook, not the print. CVS offered a first look at 2027 adjusted EPS of at least $8.44, a number that landed roughly in line with existing consensus rather than above it, and paired it with a warning that its Caremark pharmacy-benefit unit expects to lose clients next year. CFO Brian Newman addressed the figure directly on the Q2 earnings call: “While we would not normally comment on 2027 consensus this early in the year, an outlook of at least $8.44, consistent with current consensus, appears reasonable at this juncture.” Consistent with consensus, not ahead of it, was the part the market heard.
The Caremark caution has a specific cause. Federal rules on discounted 340B drug sales will pressure that unit’s profit in 2027, and CVS said its pharmacy-benefit retention rate is trending below its historical norm as it signs new contracts more cautiously. That is a real 2027 headwind stacked against a 2026 that keeps beating. The pullback to $93 reads as the market discounting guidance conservatism, not a broken earnings story.
CVS Stock Trades 25% Below a Street Target Analysts Keep Raising
Wall Street stays firmly bullish on CVS Health stock. The current split runs 18 buys, 6 outperforms, and 3 holds, with no underperform or sell ratings on the tape. Coverage holds at 27 analysts publishing targets, and the $116 mean sits 25% above the $93 close.
The direction is the more telling part. A year ago, at the June 2025 quarter, the mean target sat at $80 and the ratings skewed to 13 buys against 7 holds. Since then analysts have lifted the mean by 45%, to $116, cut the hold count to 3, and grown the buy tally to 18, all while the stock climbed from $69 to $93. The high target now reaches $148 and the low $103, so even the most cautious analyst on the tape models a price above today’s.
That climb tracks the same earnings recovery the quarter delivered: seven straight beats have pulled the Street up behind the price. The 25% gap that remains opened because targets kept rising faster than the August pullback took the stock down.
TIKR Values CVS Stock at $132, Well Above Where the Selloff Left It
TIKR’s mid-case model values CVS Health at $132 by December 2030, implying a 42% total return from the current $93 price, or 8% annualized over 4.3 years.
That return would rank CVS as a steady compounder rather than a turnaround lottery ticket, an 8% annual rate that clears a market-average bogey without demanding heroic multiple expansion.
The gap to the model’s number traces to the same 2027 caution that drove the August selloff. The market is discounting the Caremark 340B headwind and an in-line 2027 outlook, while the model weights the durability of a seven-quarter beat streak and Aetna’s margin recovery more heavily.
Should You Invest in CVS Health Corporation?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up CVS Health Corporation stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track CVS Health Corporation alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze CVS stock on TIKR for Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
